Trial · NCT07887854
Perfusion Efficiency-Guided MAP De-escalation in Elderly Septic Shock
NCT07887854, Not applicable, Not yet recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Perfusion Efficiency-Guided MAP De-escalation in Elderly Septic Shock. Trials, record NCT07887854. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887854
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perfusion Efficiency-Guided MAP De-escalation in Elderly Septic Shock
- NCT number
- NCT07887854
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Sepsis
- Interventions
- Ascending MAP titration sequence, Descending MAP titration sequence
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean difference in Tissue Perfusion Pressure (TPP) between MAP target 60-65 mmHg and 65-70 mmHg | During intervention | Mean Arterial Pressure (MAP) is the primary hemodynamic target. Tissue Perfusion Pressure (TPP) is calculated as MAP minus microvascular critical closing pressure (Pcc). Primary non-inferiority endpoint: ΔTPP = Mean TPP at 60-65 mmHg minus mean TPP at 65-70 mmHg (unit: mmHg). Non-inferiority margin set at -4 mmHg; non-inferiority is confirmed if the lower bound of one-sided 95% CI of ΔTPP ≥ -4 mmHg. TPP is calculated as MAP minus microvascular critical closing pressure (Pcc) using routine invasive arterial waveform data, no extra invasive procedures added. |
| Secondary | Perfusion Gain Efficiency (PGE) at low and high MAP intervals | During intervention | Mean Arterial Pressure (MAP) is the primary hemodynamic target. Tissue Perfusion Pressure (TPP) is calculated as MAP minus microvascular critical closing pressure (Pcc). Perfusion Gain Efficiency (PGE) is calculated as the slope of linear regression between MAP and TPP within each MAP interval (60-65, 65-70, 70-75 mmHg), reflecting the efficiency of MAP elevation in improving tissue perfusion. PGE \> 1 indicates efficient perfusion conversion; PGE ≤ 0 indicates plateau effect. |
| Secondary | Coefficient of variation of microvascular critical closing pressure (Pcc) across three MAP target intervals | During intervention | Mean Arterial Pressure (MAP) is the primary hemodynamic target. Tissue Perfusion Pressure (TPP) is calculated as MAP minus microvascular critical closing pressure (Pcc). Intra-individual variability of Pcc measured at 60-65, 65-70, 70-75 mmHg MAP stages, expressed as coefficient of variation (CV). |
| Secondary | Automated capillary refill time (aCRT) at three MAP target levels | During intervention | Mean Arterial Pressure (MAP) is the primary hemodynamic target. Standardized objective automated capillary refill time (aCRT) is measured via Mindray V700 monitor peripheral perfusion module at each stable MAP stage. |
| Other | Inflection point of MAP-TPP dose-response curve | During intervention | Mean Arterial Pressure (MAP) is the primary hemodynamic target. Tissue Perfusion Pressure (TPP) is calculated as MAP minus microvascular critical closing pressure (Pcc). Segmented linear regression to identify the MAP threshold where TPP perfusion gain plateaus or declines across 60-65, 65-70, 70-75 mmHg intervals. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887854
GET https://conductscience.org/api/trials/v1/NCT07887854/registered